# Combined cerebrospinal fluid metabolomic and cytokine profiling in tuberculosis meningitis reveals robust and prolonged changes in immunometabolic networks

Jeff Tomalka<sup>1\*</sup>, Ashish Sharma<sup>1</sup>, Alison G.C. Smith<sup>2</sup>, Teona Avaliani<sup>3</sup>, Mariam Gujabidze<sup>3</sup>, Tinatin Bakuradze<sup>3</sup>, Shorena Sabanadze<sup>3</sup>, Dean P. Jones<sup>4</sup>, Zaza Avaliani<sup>3</sup>, Maia Kipiani<sup>3</sup>. Russell R. Kempker<sup>4</sup>. Jeffrev M. Collins<sup>4\*</sup> <sup>1</sup>Department of Pathology, Emory University, Emory University School of Medicine, Atlanta, Georgia, USA <sup>2</sup>Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA <sup>3</sup> National Center for Tuberculosis and Lung Diseases, David Tvildiani Medical University, The University of Georgia, Tbilisi, Georgia <sup>4</sup> Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA \* Correspondence: Name: Jeffrey Tomalka, PhD; Email: jeffrey.alan.tomalka@emory.edu Jeffrey Collins, MD; Email: jeffrey.michael.collins@emory.edu 

### 37 Abstract

38 Much of the high mortality in tuberculosis meningitis (TBM) is attributable to excessive 39 inflammation, making it imperative to identify targets for host-directed therapies that reduce 40 pathologic inflammation and mortality. In this study, we investigate how cytokines and 41 metabolites in the cerebral spinal fluid (CSF) associate with TBM at diagnosis and during 42 TBM treatment. At diagnosis, TBM patients demonstrate significant increases versus controls 43 of cytokines and chemokines that promote inflammation and cell migration including IL-17A, 44 IL-2, TNF $\alpha$ , IFN $\gamma$ , and IL-1 $\beta$ . Inflammatory immune signaling was strongly correlated with 45 immunomodulatory metabolites including kynurenine, lactic acid, carnitine, tryptophan, and 46 itaconate. Inflammatory immunometabolic networks were only partially reversed with two 47 months of effective TBM treatment and remained significantly different versus control CSF. 48 Together, these data highlight a critical role for host metabolism in regulating the inflammatory 49 response to TBM and indicate the timeline for restoration of immune homeostasis in the CSF 50 is prolonged.

- 51
- 52 53
- -
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61

### 62 INTRODUCTION

63

Tuberculosis meningitis (TBM) is the most devastating manifestation of TB disease with 64 65 high rates of mortality and neurological morbidity.(1) While the etiology of poor clinical 66 outcomes in persons with TBM is multifactorial, including variable penetration of anti-TB drugs 67 into brain and cerebrospinal fluid (CSF),(2) an aberrant immune response in the central 68 nervous system (CNS) is thought to be a significant contributor to morbidity and mortality.(3) 69 This is supported by early animal models of TBM, which revealed that severe 70 immunopathology resulted from both live and dead bacilli.(4) Further, immune reconstitution 71 in immunosuppressed hosts with TBM, such as those with HIV infection, is a risk factor for 72 poor clinical outcomes.(5, 6) Corticosteroids, a therapy broadly targeting the immune 73 dysregulation in TBM, remain the only adjunctive treatment found to reduce mortality and 74 utilized in TBM management (7); however, they are only beneficial in a subset of patients.(8) 75 A better understanding of the host immune response in TBM is critical to develop a new 76 generation of immunomodulatory therapies that can reduce immunopathology and improve 77 clinical outcomes.

78 As with other forms of meningitis, TBM is characterized by broad upregulation of 79 proinflammatory cytokines in the CNS.(9) Yet the specific immune signaling cascades that 80 lead to poor host outcomes remain poorly understood. While increased CSF concentrations 81 of proinflammatory cytokines IL-1 $\beta$ , TNF $\alpha$ , IL-6, and IFN $\gamma$  are associated with greater disease 82 severity at diagnosis, studies to date have yielded conflicting results about their impact on 83 long-term morbidity and mortality.(8, 10, 11) Some of this variability may be due to differences 84 in host genetic (12) and metabolic factors (13, 14), which have generally gone unmeasured 85 in studies of TBM. Indeed, differences in tryptophan and eicosanoid metabolism are the only 86 host response pathways shown to impact TBM mortality.(8, 12-14) However, the relationship

between metabolic and cytokine signaling in the CNS of TBM patients and the trajectory of
 these signaling networks during treatment remain largely unexplored.

89 Recent advances in metabolomics and high-density cytokine profiling now allow for 90 high-resolution immunometabolic profiling of the CSF. Using an integrated approach with 91 these two high-resolution methods, we sought to advance our understanding of the 92 relationship between metabolism and cytokine signaling networks in the CNS of persons with 93 TBM. We first sought to understand what metabolites and cytokines in the CSF are associated 94 with TBM and TBM severity. We further aimed to determine how the host metabolic milieu in 95 the CNS may modulate immune signaling by exploring the relationship between cytokines 96 and metabolites in the CSF. Finally, we wanted to determine the time course for the resolution 97 of these immunometabolic signaling cascades over the course of TBM treatment. Our overall 98 goal was to enhance the understanding of host immunometabolic response networks to 99 Mycobacterium tuberculosis (Mtb) invasion into the CNS and to elucidate their role in 100 pathologic inflammation.(15)

### 101 MATERIAL AND METHODS

### 102 Setting and Participants with TBM

103 Persons with TBM were enrolled from the National Center for Tuberculosis and Lung 104 Diseases (NCTLD) in Tbilisi, Georgia as part of a clinical pharmacology study evaluating the 105 penetration of anti-TB drugs into the CNS.(2) Patients aged  $\geq 16$  years treated in the NCTLD 106 adult TBM ward from January 2018 to December 2019 were eligible for inclusion. All patients 107 suspected of having TBM underwent a lumbar puncture; acid-fast bacilli (AFB) staining, liquid 108 and solid culture, and Xpert MTB/RIF assay were performed on CSF. CSF samples were 109 taken at the time of TBM diagnosis and over the first 2 months of treatment. Treatment 110 regimens were individualized based on treatment history, comorbidities, and drug 111 susceptibility results when available.(16) All patients also received a 6-8-week course of

dexamethasone (400–1200mg). Written informed consent was obtained from all study
participants and study was approval was obtained from the institutional review boards of
Emory University and the NCTLD.

### 115 Asymptomatic Control Participants

De-identified CSF samples from asymptomatic persons enrolled as part of the Emory Healthy Brain Study were used as a control group for comparison to persons with TBM at diagnosis.(17) All study participants had previously provided written informed consent for use of their CSF samples in medical research.

### 120 Metabolomics analysis

121 De-identified CSF samples were randomized by a computer-generated list into blocks 122 of 40 samples prior to transfer to the analytical laboratory where personnel were blinded to 123 clinical and demographic data. Thawed CSF (65 µL) was treated with 130 µl acetonitrile (2:1, 124 v/v) containing an internal isotopic standard mixture (3.5  $\mu$ L/sample), as previously 125 described.(18) Samples were centrifuged and supernatants were analyzed using an Orbitrap 126 Q Exactive Mass Spectrometer (Thermo Scientific, San Jose, CA, USA) with dual HILIC 127 positive and c18 negative liquid chromatography (Higgins Analytical, Targa, Mountain View, 128 CA, USA, 2.1 x 10 cm) with a formic acid/acetonitrile gradient. The high-resolution mass 129 spectrometer was operated over a scan range of 85 to 1275 mass/charge (m/z).(19) Data 130 were extracted and aligned using apLCMS (20) and xMSanalyzer (21) with each feature 131 defined by specific m/z value, retention time, and integrated ion intensity.(19) Three technical 132 replicates were performed for each CSF sample and intensity values were median 133 summarized. Identities of targeted metabolites were confirmed by accurate mass, MS/MS 134 and retention time relative to authentic standards.(22)

### 135 Cytokine detection

136	The commercially available U-PLEX assay by Meso Scale Discovery (MSD) was used
137	for CSF cytokine detection. This assay allows for the evaluation of multiplexed biomarkers by
138	using custom made U-PLEX sandwich antibodies with a SULFO-TAG conjugated antibody
139	and electrochemiluminescence (ECL) detection. Direct quantitation of cytokines was
140	performed using standard curves generated by 4-fold serial dilutions of standard calibrators
141	provided by MSD. Plates were read on the QuickPlex SQ 120 using Methodical Mind <sup>™</sup>
142	software and plate data analyzed using Discovery Workbench <sup>™</sup> software (MSD).

### 143 Statistics

144 Statistical comparisons of metabolite intensity values (abundance), metabolite 145 concentrations, and cytokine concentrations were performed in R version 4.2.1. All intensity 146 values and concentrations were log<sub>2</sub> transformed and compared between groups using linear 147 regression, controlling for age and sex.(23) For untargeted analyses, a false discovery rate 148 (FDR) of q<0.10 was used.(24) Metabolic pathway enrichment analysis was performed using 149 mummichog.(25, 26) For correlation analyses, CSF metabolite and cytokine concentrations 150 were normalized using log transformation. Integrative network analyses were performed 151 using xMWAS.(27) which automatically determines the minimum association score threshold 152 required to meet the significance criteria based on the number of samples using Student's t-153 test. Only associations with an |association score|≥0.54 significant at p<0.05 were included 154 in the network analysis.

### 155 **RESULTS**

156 **Participants** 

We studied CSF samples from 17 participants with suspected TBM presenting to the NCTLD and 20 asymptomatic persons in the U.S. (**Table 1**). Among the 17 patients with suspected TBM, five (29%) were microbiologically confirmed with a median CSF white blood cell (WBC) count of 209 cells/mm<sup>3</sup>, 94% lymphocytes, a median glucose of 40 mg/dL, and total protein of 99 mg/dL. Five persons with TBM were diagnosed with multi-drug-resistant (MDR)-TBM, two of which were identified through microbiologic testing and three of which were diagnosed clinically based on a poor response to first-line therapy.

### 164 **TB** meningitis dramatically alters the CSF metabolome.

165 We detected 6,596 metabolic features in positive ionization mode and 9,427 in 166 negative ionization mode. Using an FDR-adjusted p-value of 0.1 and log2 fold-change 167 threshold of 0.5 (1.414-fold increased or decreased), we found 803 metabolic features were 168 significantly increased in the CSF of TBM patients versus controls (672 in positive ionization 169 mode and 132 in negative mode) while 806 metabolic features were decreased (708 in 170 positive mode and 98 in negative mode; Figure 1A). Metabolic pathway analysis revealed 171 vitamin D3, vitamin B3 and multiple amino acid pathways were enriched in the CSF of TBM 172 patients while caffeine metabolism and multiple pathways in carbohydrate metabolism were 173 enriched in the CSF of control participants (Figure 1B).

174 To enhance our understanding of the CSF metabolic changes associated with TBM, 175 we performed a targeted analysis of individual metabolites with confirmed chemical 176 identities.(22) Similar to the untargeted analysis, we found the CSF of TBM patients was 177 characterized by severe perturbations in energy metabolism and multiple immunomodulatory 178 metabolites including elevated concentrations of kynurenines, carnitines, amino acids, and 179 lactate and decreases in tryptophan, pantothenic acid, and itaconate (Figure 1C). 180 Hierarchical clustering analysis of significant metabolites showed almost all TBM cases 181 formed a single cluster aside from a single, unconfirmed TBM case (Figure 1D). Together,

these findings suggest a re-ordering of energy metabolism in the CNS of TBM patients, with a metabolic milieu characterized by both glycolysis and lactate accumulation as well as fatty acid activation. Further, we found CSF concentrations of immunoregulatory metabolites tryptophan, kynurenine and itaconate, all of which are known to play an important role in modulating the immune response to pulmonary TB (26, 28-30), were markedly different in TBM cases versus controls.

# Heightened inflammatory cytokines and amino acid metabolism in the CSF identify patients with TB meningitis

190 We performed a principal component analysis (PCA) of all 33 cytokines detected in 191 the CSF. We found clear separation between the two groups, which was more pronounced 192 in those with confirmed TBM (Figure 2A). This was further displayed when visualizing 193 cytokine data using a row normalized heatmap, where TBM cases separated from 194 asymptomatic controls (Figure 2B). TBM cases were characterized by marked elevations in 195 most cytokines, and particularly pro-inflammatory cytokines such as IL-17A, TNF $\alpha$ , IFN $\gamma$ , and 196 IL-1β. Increased expression of effector T cell associated cytokines including IL-2, IFNγ, IL-4, 197 IL-17A and IL-15 (31) was also observed in TBM cases while IL-7, a cytokine associated with 198 homeostasis of naïve and central memory T cells, (32) was decreased.

To determine the relationship between the metabolic and immune response in the CSF, we performed a correlation analysis of metabolite and cytokine concentrations across asymptomatic controls and persons with TBM at diagnosis. This revealed three clusters of metabolites and cytokines respectively (**Figure 3A**). Cluster 1 cytokines consisted of a large group of predominantly pro-inflammatory cytokines upregulated in TBM patients (**Figure 3B**). This cluster was significantly and positively correlated with metabolite cluster 3, primarily consisting of lactate, amino acids, carnitines, and kynurenines (**Figure 3C**). Cluster 1

206 cytokines were also significantly and negatively correlated with cluster 1 metabolites, which 207 were significantly decreased in TBM cases (Figure S1A and S1B). Cluster 2 metabolites and 208 cluster 3 cytokines did not have strong relationships with other soluble mediators, though 209 metabolite cluster 2 was also significantly increased in TBM (Figure S1C). Cytokine cluster 210 2, made up of IL-7 and IL-9, was decreased in TBM cases versus controls (Figure S2A) and 211 was weakly correlated with metabolite cluster 1 and weakly inversely correlated with 212 metabolite clusters 2 and 3. While cytokine cluster 3, which consisted of TGF<sub>β</sub>2, IFN<sub>β</sub>, 213 IFNα2a, IL-21, and IL-33, did not differ in TBM versus controls (Figure S2B), it was 214 significantly increased in patients with Grade 2 TBM versus those with Grade 1 TBM (Figure 215 **S2C**), indicating an association with disease severity.

216 To determine the network structure between clinical variables and CSF metabolite and 217 cytokine concentrations in TBM, we used a platform-independent framework for integrative 218 network analysis called xMWAS.(27) Using this approach we found TGF $\beta$ 3 played a central 219 role in the activity network, with significant associations with multiple metabolites including 220 kynurenines and carnitines (Figure 3D). While there was only one participant with TBM that 221 was HIV positive, HIV was significantly associated with type I interferons and IFNy. Confirmed 222 TBM was associated with IL-2, IFN $\gamma$ , MIP-1 $\alpha$ , IL-15, and IP-10 while TBM grade was associated with IFN<sub>B</sub>, IL-18, and IL-27. Tryptophan and epinephrine were associated with 223 224 increased CSF WBC count.

225

# Inflammatory immunometabolic changes in TBM persists for months despite appropriate treatment

We next examined the trajectory of CSF metabolite and cytokine concentrations after initiation of TBM treatment. Repeat CSF samples were examined 7, 14, 28 and 56 days after

230 treatment initiation. Of the 17 TBM patients enrolled, 3 patients were eventually deemed "non-231 responders" due to suspected or proven drug resistance, while 14 patients improved clinically 232 on anti-TB therapy. Treatment responders had significant decreases in cluster 1 cytokines at 233 14, 28, and 56 days after treatment initiation (Figure 4A). However, after 56 days of 234 appropriate treatment, CSF concentrations of these cytokines remained significantly higher 235 than in asymptomatic controls. After 7 and 14 days of treatment, the three treatment non-236 responders had higher concentrations of cluster 1 cytokines versus responders, though the 237 difference was not statistically significant (Figure 4B). Cluster 2 cytokines were lower in TBM 238 patients versus controls and did not increase with treatment (Figure S3A) while cluster 3 239 cytokines were similar to controls at baseline and throughout treatment (Figure S3B).

240 In evaluating the metabolome over the course of TBM treatment, we fount cluster 1 241 metabolites did not increase with TBM treatment and remained significantly lower than 242 controls after 56 days (Figure S4A). Cluster 1 metabolites were lower in non-responders 243 versus responders after 7 days of treatment, though the difference was not statistically 244 significant (Figure S4B). Conversely, cluster 2 metabolites were significantly lower after 28 245 days of treatment (Figure 4C) and cluster 3 metabolites were significantly lower after 28 and 246 56 days of treatment (Figure S4C). However, both remained significantly elevated after 56 247 days of treatment relative to controls. Network analysis of metabolites and cytokines during 248 TBM treatment revealed that metabolites had the strongest association with CSF WBC count 249 during treatment, including lactate, kynurenine, amino acids, and carnitines (Figure 4D). 250 Concentrations of MIP-1 $\alpha$ . IL-18 and TNF $\alpha$  were also significantly associated with CSF WBC 251 count.

### 252 **DISCUSSION**

In this study, we show that multiple metabolic signaling networks are closely associated with the CNS inflammatory response in patients with TBM and that even after

255 initiating TBM treatment, these immunometabolic changes last for an extended duration. Over 256 the course of treatment, it was metabolites, including kynurenine and multiple carnitines, that 257 were most closely associated with elevated WBCs in the CSF rather than cytokines. These 258 findings indicate that metabolic shifts in the CSF of TBM patients are an integral part of the 259 host inflammatory response. Despite recent advances in the treatment of TB disease, (33-35) 260 morbidity and mortality in persons with TBM remains unacceptably high.(1, 3) There is 261 increasing evidence that a dysregulated immune response in the CNS is a primary driver of 262 poor patient outcomes. (3, 36) Our findings strongly support the hypothesis that chronic 263 inflammation and immune dysfunction in the CNS persist despite effective TB treatment and 264 that this may be the root cause of neurological complications, morbidity, and mortality. 265 Studying the molecular networks that modulate pathologic inflammation in TBM is therefore 266 essential to discover strategies to ameliorate inflammatory immunometabolomic changes in 267 the CNS.

268 The simultaneous measurement of 33 cytokines and chemokines in the CSF is, to our 269 knowledge, the most comprehensive assessment of CSF soluble immune mediators in TBM. 270 Similar to previous studies measuring a smaller number of cytokines, we observed a 271 significant shift in the CSF cytokine profile when we compared individuals with TBM to 272 asymptomatic adults.(8, 9) Among the cytokines that were upregulated in the CSF of TBM 273 patients were key modulators of inflammatory T cell and innate immune responses including 274 IFN $\gamma$ , TNF $\alpha$ , IL-6, GM-CSF, IL-18, and IL-1 $\beta$ . We also found that TBM was associated with 275 elevation in multiple anti-inflammatory cytokines including IL-10 and TGF- $\beta$ 3. This suggests 276 that both inflammatory pathways triggered by infection and their counter-regulatory response 277 networks are increased in TBM. In our integrative analysis of TBM cases at the time of 278 diagnosis, chemokines IP-10 and MIP-1 $\alpha$  as well as cytokines IFN $\gamma$ , IL-15, and IL-2 were

significantly associated with confirmed TBM, indicating these soluble mediators are particularly active in TBM cases with higher bacterial burden. The network analysis revealed the cytokines IFN $\beta$ , IL-27, and IL-18 were significantly associated with higher TBM grade, suggesting a potential role in mediating immunopathology in severe TBM.

283 We found the concentration of multiple immunomodulatory metabolites in the CNS 284 differentiated persons with TBM from asymptomatic controls. Notably, the metabolites 285 itaconate and tryptophan were two of the few metabolites significantly decreased in the CSF 286 of TBM patients versus controls in the targeted analysis. Itaconate concentrations were 287 significantly and inversely correlated with concentrations of most inflammatory cytokines and 288 chemokines including IL-1 $\beta$ , IL-18, TNF $\alpha$ , IFN $\gamma$ , MIP-1 $\alpha$ , and MIP-3 $\alpha$ . Itaconate is derived 289 from TCA cycle intermediate cis-aconitate and has been shown to modulate inflammatory 290 signaling in macrophages through inhibition of succinate dehydrogenase (37), induction of 291 Nrf2 (38), and inhibition of inflammasome activation.(39) We have previously shown that 292 itaconate is decreased in plasma of humans with advanced pulmonary TB disease, (28) and 293 mice lacking the enzyme that forms itaconate experience pathologic pulmonary inflammation 294 and rapid mortality.(30) Itaconate has also been shown to inhibit IL-1 $\beta$ -mediated inflammation 295 in astrocytes(40) and microglia,(41) the latter of which is a primary source of inflammasomes 296 in the CNS.(42) This suggests low CSF itaconate may play a role in an overexuberant CNS 297 inflammatory response. Similar to a previous TBM metabolomics study, we also found that 298 persons with TBM had decreased CSF concentrations of tryptophan(13) and increased 299 concentrations of its immediate metabolite, kynurenine. Induction of tryptophan catabolism 300 via the enzyme indoleamine-2.3-dioxygenase-1 (IDO1) is a hallmark of TB disease regardless 301 of the affected organ system. (26) Kynurenine and its metabolites are ligands of the aryl 302 hydrocarbon receptor (AHR), which promotes differentiation of regulatory T cells (Tregs) at

303 the expense of Th17 cells.(43-45). This has the effect of limiting T cell effector function and 304 inflammation. This effect is likely protective in TBM, where decreased T cell activation would 305 be expected to reduce immunopathology. Indeed, increased tryptophan catabolism in the 306 CNS of persons with TBM has been associated with increased survival. (13, 14) We observe 307 significantly elevated Th1 (IL-2, IFN $\gamma$ ), Th2 (IL-4) and Th17 (IL-17, IL-6, TNF $\alpha$ ) effector 308 cytokines in the CSF of persons with TBM,(31) and these cytokines were correlated with CSF 309 concentrations of kynurenine and kynurenic acid. This indicates tryptophan catabolism 310 represents a counter-regulatory process to limit T-cell-mediated inflammation.(46)

311 We also found metabolic changes in the CSF of TBM patients that were consistent 312 with broad shifts in energy metabolism. Persons with TBM had significant increases in 313 multiple carnitines as well as lactate, suggesting simultaneous activation of beta-oxidation of 314 fatty acids and glycolysis. In the integrative analysis, these metabolic networks were all 315 significantly associated with TGF $\beta$  signaling. Such metabolic changes may therefore 316 stimulate TGF $\beta$  secretion or occur as a result of TGF $\beta$  upregulation. During treatment lactate, 317 kynurenine, and carnitines, along with IL-18, MIP-1 $\alpha$ , and TNF $\alpha$  were significantly associated with CSF WBC count. Elevated expression of chemokines promotes the migration of myeloid 318 319 and lymphoid cells into the CSF where they are then activated for inflammatory cellular 320 responses by cytokines including IL-1 $\beta$ , IL-6, IL-18, TNF $\alpha$ , and IFN $\gamma$ . Our data provides the 321 framework for a potential mechanism of dysregulated immune cell infiltration and activation 322 in the CSF that is driven by metabolic changes during TBM treatment.

The immunometabolic shifts seen in the CSF of TBM patients showed only minor signs of resolution after two months of effective treatment. In cluster 1 metabolites, which included tryptophan and itaconate, there was no increase over the first 2 months of treatment and these metabolites remained significantly lower than controls. While there was a significant

327 decrease in metabolite cluster 3 with treatment, which included carnitines, kynurenines, and 328 lactate, these still remained significantly elevated relative to controls. Similarly, while 329 proinflammatory cytokines and chemokines (cluster 1) decrease with effective TBM 330 treatment, these cytokines remained significantly elevated relative to controls after two 331 months of treatment. This prolonged state of abnormal immunometabolic signaling follows 332 with clinical observations that mortality in TBM patients remains elevated months to years 333 after treatment initiation.(47) It also mimics what is seen for many chronic inflammatory 334 conditions where normal immune homeostasis is permanently altered even after removal of 335 the underlying cause of the disease.(48-50) This strongly supports consideration of TBM as 336 a chronic inflammatory condition which may require longer-term immunomodulatory 337 treatment.

338 This study is subject to several limitations. Cross-sectional comparison of CSF 339 metabolite and cytokine concentrations in TBM patients were made to a control group of 340 asymptomatic individuals. This makes it more difficult to distinguish which molecular 341 signatures are specific to TBM versus meningitis due to other causes. Additionally, the 342 relatively small sample size of TBM cases from a single geographic region may limit the 343 generalizability of the study. Though we demonstrate a strong association between CSF 344 concentrations of multiple metabolites and cytokines/chemokines, the observational nature of 345 the study precludes us from establishing a causal relationship. In future studies it will be 346 important to combine systemic measurement of soluble immune modulators in the CSF with 347 transcriptional profiling of immune cells in the CNS to better understand the immune cell 348 phenotypes and signaling pathways associated with pathologic metabolic signaling in TBM. 349 Additionally, mechanistic validation of the link between key metabolites and inflammatory 350 mediators can be assessed using ex vivo or in vitro stimulation systems.

351 Overall, the data presented clearly demonstrate that soluble factors (cytokines and 352 metabolites) are critical features of the host immune environment which distinguish the 353 presence and severity of TBM. Our results provide insight into the metabolic drivers of CSF 354 inflammation in TBM, which are an integral part of inflammatory signaling networks. Given 355 the role of immunopathology in mediating adverse host outcomes in TBM, this will be a critical 356 area for further research. As these findings are expanded, it can be envisioned that signatures 357 of these host molecules could have utility as biomarkers of TBM, disease severity, and 358 response to TB treatment.

- 359
- 360

### 361 Acknowledgments

The authors thank the physicians, nurses, and staff at the NCTLD in Tbilisi, Georgia, who provided care for the patients with TBM included in this study. Additionally, the authors are thankful for study participants with tuberculosis meningitis who were willing to participate in the study and help contribute meaningful data that may help future patients with the same illness.

- 367
- 368
- 369
- 370
- 371

#### 373 **Conflict of Interest**

- 374 The authors declare that the research was conducted in the absence of any commercial or
- 375 financial relationships that could be construed as a potential conflict of interest.

#### 376 **Author Contributions**

377 All authors agree to be accountable for the content of the work. JT and JC led the data 378 analysis, integration, and interpretation, as well as manuscript writing. JT and AS led the 379 cytokine analysis and JC led the metabolomics analysis. TB and SS provided the care for all 380 patients with TBM at the National Center for Tuberculosis and Lung Diseases and helped in 381 data collection and reviewed the manuscript drafts. AGCS assisted with data collection and 382 preparation and reviewed the manuscript drafts. MK and RRK led and designed the parent 383 clinical study, led project implementation, and assisted with data interpretation and reviewing 384 the manuscript.

385

### Funding 386

387 This work was supported by grants from the National Institutes of Health (NIH) and National 388 Institute of Allergy and Infectious Diseases [R03AI139871, K23AI103044, K23AI144040, 389 P30AI168386, P30AI050409]; NIH Fogarty International Center [D43TW007124]; and NIH 390 National Center for Advancing Translational Science [UL1TR002378], Bethesda, MD, USA. 391

- 393
- 394
- 395

### 396 **References**

- Kalita J, Misra UK, Ranjan P. Predictors of long-term neurological sequelae of
   tuberculous meningitis: a multivariate analysis. Eur J Neurol. 2007;14(1):33-7.
- 399 2. Kempker RR, Smith AGC, Avaliani T, Gujabidze M, Bakuradze T, Sabanadze S, et al.
- 400 Cycloserine and Linezolid for Tuberculosis Meningitis: Pharmacokinetic Evidence of 401 Potential Usefulness. Clin Infect Dis. 2022;75(4):682-689.
- Wilkinson RJ, Rohlwink U, Misra UK, van Crevel R, Mai NTH, Dooley KE, et al.
  Tuberculous meningitis. Nat Rev Neurol. 2017;13(10):581-98.
- 404 4. Burn CG, Finley KH. The role of hypersensitivity in the production of experimental
  405 meningitis: I. Experimental meningitis in tuberculosis animals. J Exp Med.
  406 1932;56(2):203-21.
- 407 5. Quinn CM, Poplin V, Kasibante J, Yuquimpo K, Gakuru J, Cresswell FV, et al.
  408 Tuberculosis IRIS: Pathogenesis, Presentation, and Management across the Spectrum
  409 of Disease. Life (Basel). 2020;10(11).
- Pepper DJ, Marais S, Maartens G, Rebe K, Morroni C, Rangaka MX, et al. Neurologic
   manifestations of paradoxical tuberculosis-associated immune reconstitution
   inflammatory syndrome: a case series. Clin Infect Dis. 2009;48(11):e96-107.
- 413 7. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, et al.
  414 Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults.
- 415 N Engl J Med. 2004;351(17):1741-51.
- 8. Whitworth LJ, Troll R, Pagán AJ, Roca FJ, Edelstein PH, Troll M, et al. Elevated
  cerebrospinal fluid cytokine levels in tuberculous meningitis predict survival in response
  to dexamethasone. Proc Natl Acad Sci U S A. 2021;118(10).
- 419 9. Saghazadeh A, Rezaei N. Central Inflammatory Cytokines in Tuberculous Meningitis: A
- 420 Systematic Review and Meta-analysis. J Interferon Cytokine Res. 2022;42(3):95-107.

- 421 10. Koeken V, Ganiem AR, Dian S, Ruslami R, Chaidir L, Netea MG, et al. Cerebrospinal
- fluid IL-1β is elevated in tuberculous meningitis patients but not associated with
   mortality. Tuberculosis. 2021;126:102019.
- 424 11. Sharma S, Goyal MK, Sharma K, Modi M, Sharma M, Khandelwal N, et al. Cytokines
  425 do play a role in pathogenesis of tuberculous meningitis: A prospective study from a
  426 tertiary care center in India. J Neurol Sci. 2017;379:131-6.
- 427 12. Thuong NTT, Heemskerk D, Tram TTB, Thao LTP, Ramakrishnan L, Ha VTN, et al.
- 428 Leukotriene A4 Hydrolase Genotype and HIV Infection Influence Intracerebral
- 429 Inflammation and Survival From Tuberculous Meningitis. J Infect Dis. 2017;215(7):1020-
- 430 8.
- 431 13. van Laarhoven A, Dian S, Aguirre-Gamboa R, Avila-Pacheco J, Ricano-Ponce I,
  432 Ruesen C, et al. Cerebral tryptophan metabolism and outcome of tuberculous
  433 meningitis: an observational cohort study. Lancet Infect Dis. 2018;18(5):526-35.
- 434 14. Ardiansyah E, Avila-Pacheco J, Nhat LTH, Dian S, Vinh DN, Hai HT, et al. Tryptophan
- 435 metabolism determines outcome in tuberculous meningitis: a targeted metabolomic436 analysis. Elife. 2023;12.
- 437 15. Jain SK, Tobin DM, Tucker EW, Venketaraman V, Ordonez AA, Jayashankar L, et al.
  438 Tuberculous meningitis: a roadmap for advancing basic and translational research. Nat
  439 Immunol. 2018;19(6):521-5.
- Smith AGC, Gujabidze M, Avaliani T, Blumberg HM, Collins JM, Sabanadze S, et al.
  Clinical outcomes among patients with tuberculous meningitis receiving intensified
  treatment regimens. Int J Tuberc Lung Dis. 2021;25(8):632-9.
- 443 17. Goetz ME, Hanfelt JJ, John SE, Bergquist SH, Loring DW, Quyyumi A, et al. Rationale
  444 and Design of the Emory Healthy Aging and Emory Healthy Brain Studies.
  445 Neuroepidemiology. 2019;53(3-4):187-200.

- Soltow QA, Strobel FH, Mansfield KG, Wachtman L, Park Y, Jones DP. Highperformance metabolic profiling with dual chromatography-Fourier-transform mass
  spectrometry (DC-FTMS) for study of the exposome. Metabolomics. 2013;9(1
  Suppl):S132-43.
- 450 19. Go YM, Walker DI, Liang Y, Uppal K, Soltow QA, Tran V, et al. Reference
  451 Standardization for Mass Spectrometry and High-Resolution Metabolomics Applications
- 452 to Exposome Research. Toxicological sciences. 2015;148(2):531-42.
- 453 20. Yu T, Park Y, Johnson JM, Jones DP. apLCMS--adaptive processing of high-resolution
  454 LC/MS data. Bioinformatics. 2009;25(15):1930-6.
- 455 21. Uppal K, Soltow QA, Strobel FH, Pittard WS, Gernert KM, Yu T, et al. xMSanalyzer:
  456 automated pipeline for improved feature detection and downstream analysis of large457 scale, non-targeted metabolomics data. BMC bioinformatics. 2013;14:15.
- Liu KH, Nellis M, Uppal K, Ma C, Tran V, Liang Y, et al. Reference Standardization for
  Quantification and Harmonization of Large-Scale Metabolomics. Anal Chem.
  2020;92(13):8836-44.
- 23. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential
  expression analyses for RNA-sequencing and microarray studies. Nucleic Acid Res.
  2015;43(7):e47.
- 464 24. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing.
  465 Stat Med. 1990;9(7):811-8.
- Li S, Park Y, Duraisingham S, Strobel FH, Khan N, Soltow QA, et al. Predicting network
  activity from high throughput metabolomics. PLoS Comput Biol. 2013;9(7):e1003123.
- 26. Collins JM, Siddiqa A, Jones DP, Liu K, Kempker RR, Nizam A, et al. Tryptophan
  catabolism reflects disease activity in human tuberculosis. JCl Insight. 2020;5(10).

- 470 27. Uppal K, Ma C, Go YM, Jones DP. xMWAS: a data-driven integration and differential
- 471 network analysis tool. Bioinformatics. 2017.
- 472 28. Collins JM, Jones DP, Sharma A, Khadka M, Liu KH, Kempker RR, et al. TCA cycle
- 473 remodeling drives proinflammatory signaling in humans with pulmonary tuberculosis.
- 474 PLoS pathogens. 2021;17(9):e1009941.
- 475 29. Gautam US, Foreman TW, Bucsan AN, Veatch AV, Alvarez X, Adekambi T, et al. In vivo
- 476 inhibition of tryptophan catabolism reorganizes the tuberculoma and augments immune-
- 477 mediated control of *Mycobacterium tuberculosis*. Proc Natl Acad Sci U S A.
- 478 **2018;115(1):E62-e71**.
- 479 30. Nair S, Huynh JP, Lampropoulou V, Loginicheva E, Esaulova E, Gounder AP, et al. Irg1
- 480 expression in myeloid cells prevents immunopathology during *M. tuberculosis* infection.
- 481 J Exp Med. 2018;215(4):1035-45.
- 482 31. Reinhardt RL, Kang SJ, Liang HE, Locksley RM. T helper cell effector fates--who, how
  483 and where? Curr Opin Immunol. 2006;18(3):271-7.
- 484 32. Kim HR, Hwang KA, Park SH, Kang I. IL-7 and IL-15: biology and roles in T-Cell 485 immunity in health and disease. Crit Rev Immunol. 2008;28(4):325-39.
- 33. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, et al. Four Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J
- 488 Med. 2021;384(18):1705-18.
- 34. Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al.
  Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis. The
  New England journal of medicine. 2022;387(9):810-23.
- 492 35. Turkova A, Wills GH, Wobudeya E, Chabala C, Palmer M, Kinikar A, et al. Shorter
  493 Treatment for Nonsevere Tuberculosis in African and Indian Children. N Engl J Med.
  494 2022;386(10):911-22.

- Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J, et al. Prednisone
  for the Prevention of Paradoxical Tuberculosis-Associated IRIS. N Engl J Med.
  2018;379(20):1915-25.
- 498 37. Lampropoulou V, Sergushichev A, Bambouskova M, Nair S, Vincent EE, Loginicheva
- 499 E, et al. Itaconate Links Inhibition of Succinate Dehydrogenase with Macrophage
- 500 Metabolic Remodeling and Regulation of Inflammation. Cell Metab. 2016;24(1):158-66.
- 38. Mills EL, Ryan DG, Prag HA, Dikovskaya D, Menon D, Zaslona Z, et al. Itaconate is an
  anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. Nature.
  2018;556(7699):113-7.
- 39. Hooftman A, Angiari S, Hester S, Corcoran SE, Runtsch MC, Ling C, et al. The
  Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome
  Activation. Cell Metab. 2020;32(3):468-78.e7.
- 507 40. Darvish Khadem M, Tabandeh MR, Haschemi A, Kheirollah A, Shahriari A. Dimethyl
  508 itaconate reprograms neurotoxic to neuroprotective primary astrocytes through the
  509 regulation of NLRP3 inflammasome and NRF2/HO-1 pathways. Mol Cell Neurosci.
  510 2022;122:103758.
- 41. Hoyle C, Green JP, Allan SM, Brough D, Lemarchand E. Itaconate and fumarate
   derivatives inhibit priming and activation of the canonical NLRP3 inflammasome in
   macrophages. Immunology. 2022;165(4):460-80.
- 514 42. Sheppard O, Coleman MP, Durrant CS. Lipopolysaccharide-induced neuroinflammation
   515 induces presynaptic disruption through a direct action on brain tissue involving
   516 microglia-derived interleukin 1 beta. J Neuroinflammation. 2019;16(1):106.
- 43. Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, et al. Control of T(reg)
  and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature.
  2008;453(7191):65-71.

- 520 44. Desvignes L, Ernst JD. Interferon-gamma-responsive nonhematopoietic cells regulate
- 521 the immune response to *Mycobacterium tuberculosis*. Immunity. 2009;31(6):974-85.
- 522 45. Favre D, Mold J, Hunt PW, Kanwar B, Loke P, Seu L, et al. Tryptophan catabolism by
- 523 indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV
- 524 disease. Science Transl Med. 2010;2(32):32ra6.
- 525 46. Sühs KW, Novoselova N, Kuhn M, Seegers L, Kaever V, Müller-Vahl K, et al.
  526 Kynurenine Is a Cerebrospinal Fluid Biomarker for Bacterial and Viral Central Nervous
  527 System Infections. J Infect Dis. 2019;220(1):127-38.
- 528 47. Evans EE, Avaliani T, Gujabidze M, Bakuradze T, Kipiani M, Sabanadze S, et al. Long
- 529 term outcomes of patients with tuberculous meningitis: The impact of drug resistance.
- 530 PloS One. 2022;17(6):e0270201.
- 48. Nganou-Makamdop K, Talla A, Sharma AA, Darko S, Ransier A, Laboune F, et al.
  Translocated microbiome composition determines immunological outcome in treated
  HIV infection. Cell. 2021;184(15):3899-914.e16.
- Talla A, Vasaikar SV, Szeto GL, Lemos MP, Czartoski JL, MacMillan H, et al. Persistent
   serum protein signatures define an inflammatory subcategory of long COVID. Nat
   Commun. 2023;14(1):3417.
- 537 50. Meizlish ML, Franklin RA, Zhou X, Medzhitov R. Tissue Homeostasis and Inflammation.
   538 Annu Rev Immunol. 2021;39:557-81.
- 539
- 540
- 541
- 542
- 543
- 544

## **Tables and Figure Legends (Figure files submitted separately)**

### **Table 1**

	TB meningitis (n=17)	Controls (n=20)
Age, median (IQR)	36 (31-44)	59 (57-65)
Female sex, n (%)	9 (53)	10 (50)
Microbiologically confirmed TB meningitis, n (%)	5 (29)	NA
CSF total WBC, median (IQR)	209 (130-286)	NA
% Lymphocytes, median (IQR)	94 (85-96)	
% Neutrophils, median (IQR)	5 (2-8)	
TB meningitis grade, n (%)		NA
Grade 1	8 (47)	
Grade 2	9 (53)	

556 Figure 1 – (A) Volcano plot showing m/z features that were differentially abundant in the 557 cerebrospinal fluid of TBM cases versus controls. Those significantly increased in the CSF of 558 TBM cases (log2 fold change  $\geq 0.5$  and FDR-corrected p-value < 0.1) are in red while those 559 increased in the CSF of control participants are in blue. (B) Metabolic pathway analysis 560 showing metabolic pathways significantly enriched (p<0.05) in TBM CSF (red) and those 561 significantly enriched in control CSF (blue). (C) Volcano plot of targeted metabolites 562 significantly increased in the CSF of TBM cases (red; log2 fold change ≥ 0.5 and FDR-563 corrected p-value < 0.1) and those increased in the CSF of control participants (blue). 564 \*Itaconate is isobaric with citraconate and mesoconate. (D) 2-way hierarchical clustering 565 analysis of targeted metabolites that significantly differed in TBM CSF versus control CSF. 566 Each column is annotated by whether the participant was diagnosed with TBM (red) versus 567 controls (blue), whether TBM was microbiologically confirmed (dark blue) or not (yellow), and 568 whether a TBM case had Grade 1 (grey) versus Grade 2 (green) severity.

569

570 Figure 2 – (A) Principal component analysis of all 33 cytokines measured in the CSF showing 571 clear separation between control CSF (blue) and those with microbiologically confirmed TBM 572 (red) while those with unconfirmed TBM (purple) had some overlap with both groups. Principal 573 component 1 (x-axis) captured 59% of the variation in the data while principal component 2 574 (y-axis) captured 8%. (B) 2-way hierarchical clustering analysis of all measured cytokines 575 annotated by whether the participant was diagnosed with TBM (red) versus controls (blue), 576 whether TBM was microbiologically confirmed (dark blue) or not (yellow), and whether a TBM 577 case had Grade 1 (grey) versus Grade 2 (green) severity.

579 Figure 3 – (A) Pearson correlation heatmap of cytokines (x-axis) and differentially abundant 580 metabolites (y-axis) in controls (n=20) and TBM cases at baseline (n=14) with 2-way 581 hierarchical clustering. (B) Comparison of the centroid score of cluster 1 cytokines and (C) 582 cluster 3 metabolites in TBM cases at baseline versus controls. Groups were compared using a Wilcoxon rank sum test (\* $P \le 0.05$ , \*\*P < 0.01, \*\*\*P < 0.001). (D) Unbiased network analysis 583 584 showing all significant relationships between clinical characteristics of persons diagnosed 585 with TBM and cytokine and metabolite concentrations in CSF at the time of diagnosis. Positive 586 associations are denoted with red edges while negative associations are denoted with blue 587 edges. The intensity and width of the line corresponds to the strength of the association.

588

589 **Figure 4** – (A) Boxplots showing changes in cluster 1 cytokines after 7, 14, 28, and 56 days 590 of treatment in persons with TBM who clinically responded to therapy. (B) after 7 and 14 days, 591 treatment non-responders had elevated concentrations of cluster 1 cytokines versus 592 responders. (C) Cluster 3 metabolites also significantly declined in the CSF in treatment 593 responders. Cross sectional measures were compared with a Wilcoxon rank sum test while 594 repeat measures used a Wilcoxon signed rank test: \* p<0.05, \*\* p<0.01, \*\*\* p<0.001. (D) 595 Unbiased network analysis showing all significant relationships between clinical 596 characteristics of persons diagnosed with TBM and cytokine and metabolite concentrations 597 in CSF during treatment. Positive associations are denoted with red edges while negative associations are denoted with blue edges. The intensity and width of the line corresponds to 598 599 the strength of the association.

600

Supplemental Figure 1 – (A) Cluster 1 metabolites including (B) tryptophan were significantly decreased in the CSF of persons diagnosed with TBM versus asymptomatic controls. (C) Cluster 2 metabolites were significantly increased in TBM versus asymptomatic controls. Groups were compared using a Wilcoxon rank sum test (\*P  $\leq$  0.05, \*\*P < 0.01, \*\*\*P < 0.001).

607

Supplemental Figure 2 – (A) Cluster 2 cytokines (IL-7 and IL-9) were significantly lower in the CSF of TBM patients versus asymptomatic controls while (B) Cluster 3 cytokines did not differ between groups. (C) Cluster 3 cytokines were significantly increased in those with Grade 2 TBM versus those with Grade 1 TBM. Groups were compared using a Wilcoxon rank sum test (\*P  $\leq$  0.05, \*\*P < 0.01, \*\*\*P < 0.001).

613

Supplemental Figure 3 – (A) Cluster 2 cytokines did not increase in the CSF in treatment responders after 7, 14, 28, and 56 days of treatment and remained significantly lower than asymptomatic controls. (B) Cluster 3 cytokines did not change with TBM treatment and remained similar to concentrations in the CSF of asymptomatic controls. Cross sectional measures were compared with a Wilcoxon rank sum test while repeat measures used a Wilcoxon signed rank test: \* p<0.05, \*\* p<0.01, \*\*\* p<0.001.

620

621

623 **Supplemental Figure 4** – (A) Cluster 1 metabolites did not increase in the CSF in treatment 624 responders after 7, 14, 28, and 56 days of treatment and remained significantly lower than 625 asymptomatic controls. (B) Cluster 1 metabolites were lower in treatment non-responders 626 after 7 days of treatment versus treatment responders. (C) Cluster 2 metabolites significantly 627 decreased over the course of TBM treatment but remained significantly increased versus 628 asymptomatic controls. Cross sectional measures were compared with a Wilcoxon rank sum 629 test while repeat measures used a Wilcoxon signed rank test: \* p<0.05, \*\* p<0.01, \*\*\* 630 p<0.001.









Baseline Day 7 Day 14 Day 28 Day 56 Control